Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Shanghai Kaibao Pharmaceutical Co's FCF Margin % or its related term are showing as below:
SZSE:300039'
s FCF Margin % Range Over the Past 10 Years
Min: 7.59 Med: 18.45 Max: 30.82
Current: 16.06
During the past 13 years, the highest FCF Margin % of Shanghai Kaibao Pharmaceutical Co was 30.82%. The lowest was 7.59%. And the median was 18.45%.
SZSE:300039's FCF Margin % is ranked better than 83.44% of 960
companies
in the Drug Manufacturers industry
Industry Median: 2.36
vs SZSE:300039: 16.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Kaibao Pharmaceutical Co FCF Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Kaibao Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Kaibao Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Kaibao Pharmaceutical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Kaibao Pharmaceutical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Kaibao Pharmaceutical Co (SZSE:300039) has a FCF Margin % of 16.18% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shanghai Kaibao Pharmaceutical Co and its competitors. This is 12% below median its historical median of 18.45. Over the past decade, Shanghai Kaibao Pharmaceutical Co's FCF Margin % has ranged from 7.59 to 30.82. According to the industry distribution chart, Shanghai Kaibao Pharmaceutical Co ranks #159 out of 960 companies in the Drug Manufacturers industry, placing it in the top 16.6%.
Is Shanghai Kaibao Pharmaceutical Co's FCF Margin % too high?
Shanghai Kaibao Pharmaceutical Co's current FCF Margin % of 16.18% is 12% below median its 10-year median of 18.45. Over the past 10 years, this metric has ranged from a low of 7.59 to a high of 30.82. The Drug Manufacturers industry median FCF Margin % is 2.36. Shanghai Kaibao Pharmaceutical Co's value of 16.18% is 585.6% above this industry median. Based on the distribution chart, Shanghai Kaibao Pharmaceutical Co ranks #159 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Kaibao Pharmaceutical Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Kaibao Pharmaceutical Co's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Kaibao Pharmaceutical Co ranks #159 out of 960 companies for FCF Margin %. This places Shanghai Kaibao Pharmaceutical Co in the top 17% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.36. Shanghai Kaibao Pharmaceutical Co's value of 16.18% is 585.6% above this benchmark. Historically, Shanghai Kaibao Pharmaceutical Co's own FCF Margin % has ranged from 7.59 to 30.82 over the past decade. While the company's 10-year median is 18.45 vs. the industry median of 2.36, Shanghai Kaibao Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.36, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Kaibao Pharmaceutical Co's current FCF Margin % of 16.18% is 585.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shanghai Kaibao Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Kaibao Pharmaceutical Co's current FCF Margin % is 16.18%, which is 12% below median its own 10-year median of 18.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Kaibao Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Kaibao Pharmaceutical Co (SZSE:300039) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥4.65, compared to a current price of ¥6.03 — trading 29.7% above its estimated fair value. The current FCF Margin % is 16.18%, which is 12% below median its 10-year median of 18.45 and 585.6% above the Drug Manufacturers industry median of 2.36. Shanghai Kaibao Pharmaceutical Co's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Shanghai Kaibao Pharmaceutical Co (SZSE:300039), the current FCF Margin % is 16.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Kaibao Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥6.03 is trading 29.7% above its estimated GF Value™ of ¥4.65.
GuruFocus considers Shanghai Kaibao Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SZSE:300039:
FCF Margin %: 16.18% (12% below median its 10-year median of 18.45)
GF Value™: ¥4.65 vs. price of ¥6.03 (29.7% above fair value)
Industry Position: 585.6% above the Drug Manufacturers median (#159 of 960)
No single metric tells the full story. See the SZSE:300039 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.
72GF Score
Get the complete analysis for SZSE:300039
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300039 has been successfully added to your 
